ADMA Biologics (ADMA) Tops Q3 EPS by 2c
Tweet
Share
E-mailGet Alerts ADMA Hot Sheet
Join SI Premium – FREE
ADMA Biologics (NASDAQ: ADMA) reported Q3 EPS of $0.15, $0.02 better than the analyst estimate of $0.13. Revenue for the quarter came in at $119.8 million versus the consensus estimate of $105.96 million.
For earnings history and earnings-related data on ADMA Biologics (ADMA) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BofA Securities Upgrades Cintas (CTAS) to Buy
- FDA approves Merck's Lipfendra as first oral PCSK9 inhibitor
- BofA Securities Downgrades W.R. Berkley (WRB) to Underperform
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
